NCT06916793

A Phase 3 Study to Evaluate the Safety and Efficacy of CKD-843 in Male Patients With Androgenetic Alopecia

A Randomized, Double-blind, Multi-center, Placebo-controlled, Parallel-group Phase 3 Trial to Evaluate the Efficacy and Safety of CKD-843 in Male Patients With Androgenetic Alopecia

• Status: Not Yet Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 288 (estimated)
• Sponsor: Chong Kun Dang Pharmaceutical · Industry
• Sex: Male
• Age: 18 Years – 50 Years
• Healthy volunteers: Not accepted

Summary

This is a multi-centers, randomized, double-blind, parallel-group, Phase 3 Trial to evaluate the efficacy and safety of CKD-843 in Male patients with Androgenetic Alopecia

Detailed description

The participants were randomly assigned to one of the following groups: CKD-843 dose #1, CKD-843 dose #2, placebo, or Dutasteride group. They received the assigned medication, placebo for blinding, or the reference drug over a 12-month period.

Conditions

• Androgenetic Alopecia

Interventions

Type	Name	Description
DRUG	CKD-843 dose#1	IM injection every 3 months for 12 months
DRUG	CKD-843 dose#2	IM injection every 3 months for 12 months
DRUG	Placebo of CKD-843 dose	IM injection every 3 months for 12 months
DRUG	Dutasteride Capsules	oral, once daily, 12 months
DRUG	Placebo of Dutasteride Capsule	oral, once daily, 12 months

Timeline

• Start date: 2025-04-30
• Primary completion: 2026-12-19
• Completion: 2027-09-17
• First posted: 2025-04-08
• Last updated: 2025-04-08

Locations

1 site across 1 country: South Korea